Compare SER & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SER | PMN |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.3M | 23.5M |
| IPO Year | 2018 | N/A |
| Metric | SER | PMN |
|---|---|---|
| Price | $1.70 | $14.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $13.00 | ★ $42.67 |
| AVG Volume (30 Days) | ★ 3.6M | 443.7K |
| Earning Date | 03-23-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $116,000.00 | N/A |
| Revenue This Year | $134.46 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.71 | $6.27 |
| 52 Week High | $7.92 | $39.75 |
| Indicator | SER | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 31.98 | 68.93 |
| Support Level | $2.11 | $8.96 |
| Resistance Level | $3.14 | $15.05 |
| Average True Range (ATR) | 0.35 | 1.91 |
| MACD | -0.12 | 0.08 |
| Stochastic Oscillator | 2.03 | 54.27 |
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.